A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
Inclusion Criteria
Inclusion Criteria
- Colorectal cancer.
- Recurrent tumor following treatment with irinotecan and/or oxaliplatin.
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney, and liver function.
Exclusion Criteria
- Pregnant or breast feeding.
- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
- Prior radiation therapy.
- CNS metastasis.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Objective Response Rate in subjects with Recurrent Colorectal Cancer
Outcome Time Frame:
1 year
Principal Investigator
Helen Eliopoulos, MD
Investigator Role:
Study Director
Investigator Affiliation:
Abbott
Authority:
United States: Food and Drug Administration
Study ID:
M02-446
NCT ID:
NCT00073138
Start Date:
August 2003
Completion Date:
February 2005
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|---|
| Duke University Medical Center | Durham, North Carolina 27710 |
| Northwestern University | Chicago, Illinois 60611 |
| University of Chicago Medical Center | Chicago, Illinois 60637 |
| Cancer Institute Medical Group | Los Angeles, California 90025 |
| University of Southern California | Los Angeles, California 90033 |
| University of Wisconsin Medical Center | Madison, Wisconsin 53792 |
